Mathias Uhlén is a co-founder of Affibody AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. He is a Program Director of the Swedish Human Protein (HPA) program, funded by the Knut and Alice Wallenberg foundation, and a Board member of Atlas Antibodies AB (Chairman), Antibodypedia AB, Bure AB, Novozymes AS, Atlasab Intressenter AB and SweTree Technologies AB
His research in Biotechnology